Active	Status	Sponsor type	Region	Phase	Filter
6 Active 12 Inactive 18 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ortel, Thomas L
NCT03393975 / 2017-000858-18: A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)	Completed	3	51	Europe, Japan, US	BAX930, rADAMTS13, SHP-655, TAK-755, recombinant ADAMTS13, BAX 930, Standard of care	Baxalta now part of Shire, Takeda Development Center Americas, Inc.	Thrombotic Thrombocytopenic Purpura (TTP)	12/23	05/24
NCT04683003: A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura	Recruiting	3	77	Europe, Japan, US, RoW	TAK-755, rADAMTS13; recombinant ADAMTS13; SHP-655; BAX 930	Takeda, Takeda Development Center Americas, Inc., Shire	Thrombotic Thrombocytopenic Purpura (TTP)	03/27	03/27
NCT05785819: A Phase 2 Study of VLX-1005 Versus Placebo in Suspected Heparin Induced Thrombocytopenia	Recruiting	2	60	US	VLX-1005, 12-LOX enzyme inhibitor, Placebo, Inactive substance similar in appearance to VLX-1005	Veralox Therapeutics	Thrombocytopenia, Immune, Heparin Induced Thrombocytopenia	12/24	03/25
NCT05714969 / 2022-001940-36: A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)	Active, not recruiting	2	40	Europe, US, RoW	TAK-755, rADAMTS13, recombinant ADAMTS13, SHP-655, BAX 930	Takeda, Takeda Development Center Americas, Inc.	Thrombotic Thrombocytopenic Purpura (TTP)	03/25	03/25
DARE-APS, NCT05671757: Daratumumab in Primary Antiphospholipid Syndrome	Recruiting	1/2	22	US	Daratumumab, DARZALEX, DARZALEX®	National Institute of Allergy and Infectious Diseases (NIAID), Immune Tolerance Network (ITN), PPD DEVELOPMENT, LP, Rho Federal Systems Division, Inc.	Autoimmune Disorders	06/26	03/27
NCT00482794: Genetic Risk Factors Associated With Antiphospholipid Antibody Syndrome	Recruiting	N/A	2800	US		Duke University	Antiphospholipid Syndrome	12/24	12/24